X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (78) 78
index medicus (60) 60
female (53) 53
male (40) 40
adult (30) 30
animals (29) 29
clinical neurology (24) 24
middle aged (24) 24
epilepsy (22) 22
levetiracetam (20) 20
adolescent (19) 19
seizures (18) 18
child (17) 17
tuberculosis (17) 17
young adult (17) 17
anticonvulsants - therapeutic use (16) 16
mice (16) 16
pharmacokinetics (16) 16
pharmacology & pharmacy (16) 16
treatment outcome (16) 16
analysis (15) 15
antiepileptic drugs (15) 15
piracetam - analogs & derivatives (15) 15
drug therapy (13) 13
neurology (13) 13
care and treatment (12) 12
cell line (12) 12
double-blind (12) 12
oncology (12) 12
aged (11) 11
anticonvulsants - adverse effects (11) 11
drug resistance (11) 11
mycobacterium tuberculosis - drug effects (11) 11
neoplasm invasiveness (11) 11
tumor cells, cultured (11) 11
antitubercular agents - pharmacology (10) 10
child, preschool (10) 10
efficacy (10) 10
microbiology (10) 10
clinical trials (9) 9
double-blind method (9) 9
idiopathic generalized epilepsy (9) 9
lamotrigine (9) 9
mycobacterium-tuberculosis (9) 9
anticonvulsants (8) 8
anticonvulsants - administration & dosage (8) 8
chemistry, medicinal (8) 8
internal medicine (8) 8
piracetam - adverse effects (8) 8
piracetam - therapeutic use (8) 8
structure-activity relationship (8) 8
administration, oral (7) 7
antitubercular agents (7) 7
antitubercular agents - therapeutic use (7) 7
atp synthase (7) 7
biochemistry & molecular biology (7) 7
drugs (7) 7
follow-up studies (7) 7
invasion (7) 7
mice, nude (7) 7
microbial sensitivity tests (7) 7
neurosciences (7) 7
safety (7) 7
tolerability (7) 7
abridged index medicus (6) 6
bedaquiline (6) 6
chick embryo (6) 6
children (6) 6
dose-response relationship, drug (6) 6
drug administration schedule (6) 6
drug therapy, combination (6) 6
epilepsy - drug therapy (6) 6
epilepsy, generalized - drug therapy (6) 6
immunology (6) 6
in-vitro (6) 6
infectious diseases (6) 6
medicine & public health (6) 6
pharmacology/toxicology (6) 6
phenotype (6) 6
placebo-controlled trial (6) 6
research (6) 6
respiratory system (6) 6
retrospective studies (6) 6
therapy (6) 6
tuberculosis, multidrug-resistant - drug therapy (6) 6
age factors (5) 5
cancer (5) 5
diarylquinoline tmc207 (5) 5
electroencephalography (5) 5
gastroenterology and hepatology (5) 5
growth (5) 5
in vitro techniques (5) 5
infant (5) 5
monotherapy (5) 5
multicenter (5) 5
mycobacterium tuberculosis (5) 5
prospective studies (5) 5
psychiatry (5) 5
rats (5) 5
susceptibility (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2014, Volume 371, Issue 8, pp. 723 - 732
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2009, Volume 360, Issue 23, pp. 2397 - 2405
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 12/2017, Volume 196, Issue 12, pp. 1612 - 1615
[...]we did not examine grades of positivity within triplicates but consider it beyond the scope of this work. [...]collection of triplicate instead of single... 
RESPIRATORY SYSTEM | TUBERCULOSIS | CRITICAL CARE MEDICINE | Studies | Multidrug resistant organisms | Tuberculosis | Laboratories | Research & development--R&D | Patients | Correspondence
Journal Article
Gastroenterology, ISSN 0016-5085, 2010, Volume 138, Issue 3, pp. 913 - 921
Background & Aims The search for targeted anti-hepatitis C virus (HCV) drugs is driven by the adverse effect profile and limited efficacy of the current... 
Gastroenterology and Hepatology | HCV | Phase-1 Study | Protease Inhibitor | TMC435 | PLUS RIBAVIRIN | INTERFERON-ALPHA-2B | VIRUS | TELAPREVIR | SAFETY | GENOTYPES 1 | INFECTED INDIVIDUALS | THERAPY | PEGINTERFERON ALPHA-2A | GASTROENTEROLOGY & HEPATOLOGY | Simeprevir | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | DNA, Viral - analysis | Male | RNA, Viral - blood | Young Adult | Time Factors | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Hepacivirus - drug effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Viral Nonstructural Proteins - genetics | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Hepatitis C - diagnosis | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Sulfonamides - adverse effects | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sulfonamides - administration & dosage | Medical colleges | Medical research | Protease inhibitors | Proteases | Interferon alpha | Medicine, Experimental | Biological response modifiers | Hepatitis C
Journal Article
Journal of Biopharmaceutical Statistics, ISSN 1054-3406, 05/2019, Volume 29, Issue 3, pp. 468 - 477
Surrogate endpoints need to be statistically evaluated before they can be used as substitutes of true endpoints in clinical studies. However, even though... 
Causal inference | Fano's inequality | surrogate endpoints | Fano’s inequality | PHARMACOLOGY & PHARMACY | STATISTICS & PROBABILITY | CAUSAL-INFERENCE
Journal Article
Royal Society Open Science, ISSN 2054-5703, 03/2018, Volume 5, Issue 3, p. 172437
While the diversity of 'southern seals', or Monachinae, in the North Atlantic realm is currently limited to the Mediterranean monk seal, Monachus monachus,... 
Monachinae | Neogene | North Atlantic | Biodiversity | Phocidae | WHALE | biodiversity | MULTIDISCIPLINARY SCIENCES | MAMMALIA | SEALS | LATE MIOCENE | CETACEA
Journal Article
Journal Article
Advances in Therapy: the international journal of drug, device and diagnostic research, ISSN 0741-238X, 11/2019, Volume 36, Issue 11, pp. 3059 - 3070
textabstractIntroduction: Forced vital capacity is the only registrational endpoint in idiopathic pulmonary fibrosis clinical trials. As most new treatments... 
Data simulation | Modelling | Respiratory | Forced vital capacity | Idiopathic pulmonary fibrosis | Medicine & Public Health | Rheumatology | Internal Medicine | Oncology | Cardiology | Pharmacology/Toxicology | Endocrinology | Original Research
Journal Article
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 52, pp. S416 - S416
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 52, pp. S416 - S416
Journal Article